[Form 4] Channel Therapeutics Corporation Insider Trading Activity
Rhea-AI Filing Summary
Form 4 highlights for Pelthos Therapeutics Inc. (PTHS) filed 07/03/2025:
- Reporting person: Todd C. Davis, identified as both a Director and 10% Owner of the issuer through his role as CEO and director of Ligand Pharmaceuticals Inc. ("Ligand").
- Non-derivative transaction: On 07/01/2025, 1,500,000 shares of common stock were acquired (Code C – conversion) at an effective price of $10 per share following the conversion of Series A preferred stock. Post-transaction indirect holding (via Ligand) stands at 1,500,000 shares. A small disposition of 2,917 common shares is also reported.
- Derivative transactions: • 15,000 shares of Series A convertible preferred stock were converted into 1,500,000 common shares (Code C). • 31,278.681 shares of Series A convertible preferred stock were received (Code J – merger related), representing 3,127,868 underlying common shares. Remaining indirect derivative position totals 3,127,868 common share equivalents.
- Corporate actions: All share figures reflect a 1-for-10 reverse stock split effected on 07/01/2025. The preferred shares are convertible at any time but subject to a 49.9% ownership cap.
- Merger context: Securities were received in exchange for LNHC, Inc. shares in connection with the merger of CHRO Merger Sub, Inc. into LNHC, a wholly-owned Ligand subsidiary, under the 04/16/2025 Merger Agreement.
The filing signals a substantial increase in Mr. Davis’s indirect equity exposure to Pelthos through Ligand, aligning his economic interests with common shareholders while also disclosing the structural changes stemming from the merger and reverse split.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider converted preferred into 1.5 M shares and gained 3.13 M more via merger, raising indirect stake post-reverse split.
From a capital-structure standpoint, the conversion of 15,000 Series A preferred shares removes a senior security layer and increases the free-float by 1.5 million shares. The follow-on receipt of 31,278.681 preferred shares adds a potential 3.13 million shares of overhang, although conversion is capped at 49.9% ownership. The reverse split makes per-share metrics clearer but does not alter underlying value. Overall, Davis—through Ligand—now controls roughly 4.63 million common share equivalents, cementing strategic influence. While not a cash purchase, the insider’s enlarged position may be interpreted as a vote of confidence and aligns interests ahead of post-merger integration.
TL;DR: Director/10% owner’s stake climbs; governance focus shifts to mitigating conversion-related dilution risk.
The filing underscores significant concentration of ownership: Davis, via Ligand, now beneficially owns >10% of Pelthos stock, reinforcing control. The 49.9% conversion blocker protects minority holders, yet the sizeable derivative position still represents potential dilution. Board oversight will be needed to balance Ligand’s influence with independent director responsibilities. Transparent disclosure of the merger exchange ratio and split adjustment helps meet Section 16 obligations, reflecting sound compliance practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Convertible Preferred Stock | 15,000 | $0.00 | -- |
| Other | Series A Convertible Preferred Stock | 31,278.681 | $0.00 | -- |
| Conversion | Common Stock | 1,500,000 | $10.00 | $15.00M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. Received in exchange for shares of LNHC, Inc. ("LNHC") common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand.
